—
.

.

.

.

9.

. 2002

(. …, ..) (. …, . ..) .

— , . , .

: … .., ..( ), … .., .., .., ..

: , , …, .., 1. 11. 2001 .

: , , .., 1. 11. 2001 .

. , ( .., .. 1984; 1998).

, , . , ( , ) , ( . 1993; ., 1997).

, , , . , , , .

9 . . 20 4 .

:

1. . .

2. .

3. — , .

4. , .

5. .

6. .

7. , , , — .

1 — ( , , , ). .

2 — — 9.

3 — ( 9, , — ).

1 — ( , , , ).

2 — ( ). 9 ( ).

3 — — 9.

4 — ( 9, , , ).

, , .

( ).

, — . , , , .

, , , (). , . , :

.

3 : ( ), ( ) ( ).

. 5-7% . ( ), .

, , , . , , , .

, — .

, 1 , .

.

15% , , . , 15%, , , , , .

. , ( ., . 1997) 5 3 54-56% .

. . , , , , ( .., .., .., .., .. 1998).

, , — , , , , () .

. 1.

20 — , 60 49,3% .

. 2. .

: , 20 (9,5% ).

, . : , — , . .

1.

, , , . , 1 2,8 , 1,3 , 1,2 . 3,3 , 1,3 1,6 .

.

, , . 200 . :

— , , . (TNF) 1,6, 10. ( ). , . , .

, — 1, 6 , — 6 . . TNF — 1 — 6. — 1 6 , . , 1 6 , — . — , ,, , , a — , , .

— . , , . , , , , , .

( NO ) — — , , .

— , , , .

— . , — . , .

— , . — . — , , .

— , , , .

, .

.

— . . , , — . :

• 38o 36o
• 90
• 20 32
• 12 000 4 000 , 10 %

: 1. — . , . 2. . , , . , -1, 10, 13, . , , , . 3 . . , , , , , — .

, , , , . , , .

.

() N.ylney . (1973) . . .Baue (1975), B.Eisman (1977) D. Fry (1980-1982) .

, .., .., .., .., .. , .., .. , .. . — .

( ) — , — , , .. , . , , , .

— 20 75-80 % . 21 , 85 000 . 300 000 .

: 1. , , ; 2. , , — , , ; 3. , , . , — , , , , .

2.

: 473 338 (71,4%) — . , , ( ) , . 44,6%, 47,3%, 43,7% 47,1%.

(29,5% ). , . , 2-3 .

— () . — , , , , — , — — ( .. 1997; .., .., .. 1998).

, — , , ( Doughty L . A ., Kaplan S . S ., Carcillo J . A . 1996). ,

, 2 120 200% . , , , ( Luce P . V . 1998).

.3. — .

, — . (- ) — ( AaDpO 2) . AaDpO 2 . , . (2) (Pv2).

— , , . , — . — , .

: (, ), , , ( ).

— 47,3% . .

. 4

( ) , . , , . , , ( Reinhart K ., Hanneman L ., Meir — Hellmann A ., Specht M . 1994).

— . , . , .

— , , — , , , .

, . , , . , , .

.. , — .

3.

, , , . . , : 30%, , , , .

, (. 4).

( S 20%)

. , , 20% , 4 , 1,8 1,5 — .

5 31-40% .

(S 31-40%)

, 31-40% 3 , 1,5 1,3 .

, , .

.

1. .
2. .
3. .
4. .
5. — .

.

, . 24 , . .

, . 7 , , 30% ( ), , , — ( ) , 24 .

:

1. : , , 0,6 1,0 . . .

2. — , . , .

3. : ( ) .

4. — ( ) , . ( ). (, 5-10% ) (, , ), . .

5. . 6 .

:

— .

:

3 : 5 () % + . .

3 : 3 () % + . .

:

N % + . , N — (1,2 3).

— 15%.

8 12 ( ), 16 .

1 :

5% 10% : = 1:1.

3 :

( 10 40 .., 100 300 ..), , (1,25 2,5 \). — . :

, . , , 7,2% — 7,5% NaCl 4 5 20 . , . ( ) .

( 0,1 1% ) (, , 1 , 1 .) 4-6 .

( , ). .

, , , , .

(, ). .

— . (, ) , . (, , , ) , .

15% , . 3 \ .

.

Fi 2 0,45 — 0,6 0,3.

. :

1. .

2. , , , .

3. : ( 12%, SO 2 94%, 2 80 , 2 Fi 2 370 ).

, ( ), , . . 23,2 +- 3,1 . 11,3 +- 2,0 ., — 54,9 +- 4,2 . 38,6 +- 3,6 .

. ( SIMV ) +18 2 3,5 2 30 5 . , — , , ( PCV ) 22 2 () 7,5 2.

, . , . SIMV PCV 20 2. 3 2 30 4-5 . FiO 2 ( 0,6) : = 1:1.

SIMV + PCV ( PCV — IRV ). 24 , FiO 2 0,35 .

1 . :

(, ), .

(, ) , .

40% 24 . — . — , . , — .

. — , . (, , , ), — (20% ) ( , ).

— ( + ) . 70% . (, , , ). .

, , , . . Lund and Browder , 1994:

6.

(%)

.

, .

1 — , , ( ).

2 — ( , ). — , , , , 2-4 .

3 — , , , , () () — , , -, , , , .

3 — () () . , , — -, , , . , , , — , -, , . . .

4 — , , — , , , . , , , — . , .

(1, 2, 3 ) , . (3 4 ) .

( ), ( , , ). — , , . , , , . . 15%. .

, , . . 1% 1% . 10 30 — .

60 . 60 90 . 90 .

( ). , . , (, ). .

, , ,

( ).

— , , (, , ) , , , , .

. (, , ) (, ). , .

( ), (, + ). — + , . (, + ).

, , , . . 20% .

, (1 250 ), .

(2-4- ) — . .

3 , , . , , ( ), , .

.

1. .
2. .
3. .
4. 30%.
5. .
6. .
7. .
8. .
9. .

. . .

. . , , , .

:

1. 1
2. 1 ( ).
3. .
4. .
5. .

:

1. , , . 6 12 .
2. .
3. 6 , 12 .
4. , .
5. : (, , ), , , , , , . — , , — , .
6. : , , , , — .
7. — , 8 .

Ht , , , .

:

1. .
2. — , , , , , — .
3. , .
4. 2 .

-. , , , 100 . : , , , , ( .., .. 1986; .., .., .., .. 1989).

— , . . .

1986 . . , . 50 . , .

290 000 . . — , , ( .., .. 1980). , 40-50 . .

: , , . — (), , . — . , .

(). .

. 5. .

() . , , ( , ). .

. 6.

, : . , , 5-7 , . , , . , , , .

. , ( ). , . , .

( ,

, 1991 R . Bone 1991, 1994 ..)

1. ( , ).
2. ( ).
3. . , (, , ).
4. () . , .

, , .

, . . — .

.

1. .

, ( , ) , . , . .

. , .

() -. , , , :

1. .
2. .
3. .
4. .

. , . (, , , ), , Fi 2 0,21 1,0 .

2. .

. , — , , ( PCV ) 22 2 () 7,5 2.

. 7. ( .. 1997)

1997 , . , .

. 8. ( .., 1997)

3. () .

, . , , .

: , — (). — :

• ( 10% ). .
• . , .

7.

, , . .

. . , 24 . , 16 — 18 , .

, , , (, -, , ) 5050 (). . .

. . . ( 30 , 300 ) , 20 .

, , 15 . , (. ), ( 2000), (-) (, ..).

, 15 13 , , . ( — — ). ( ) .

: 1. . 2. . 3. .

: 1. , 2. , 3. .

: (10% 20% 8-15 , ), ( 3 0,15 , .. 100 ) (, , , 10%, 1,0-2,5 0,1 , ).

4. .

30 , , , -. , , 0,2 0,3 70-100 . . . , , . 0,001-0,003 , 0,02-0,08 0,15-0,25 . . , ( 0,25 ). — .

—

.

9: . , . 51. . 52-08-49.

— (52-08-49).

(52-02-29).

(52-02-29)

— . 46-64-61(2).

:

1. . : . 4, 1998, . 32 33.
2. .., .., .., .., .. , 2 . 1, 1998, . 4 7.
3. .., .., .., .. , . . 2, 1998, . 8 12.
4. .., .., .. , . 2, 1998, . 7 16.
5. ., . . . . 1997, . 168 170.
6. .., .. . 5, 1980, . 33 37.
7. .. .. . — 8, 1984, . 27 30.
8. .., .. . , 1998, 2, . 17-18.
9. .., .., .. . ( ). , 2000, 19 .
10. .., .. , . 8, 31, 1986, . 49 54.
11. .. . . . . . , , 1997, 30 .
12. .., .. . , 6 , 2000, , . 207.
13. .., .., .. . , 1, 2000, . 47-50.
14. .., .., : . , 1999, 4, . 28-31.
15. .., .., .. . . , , , , 2000, . 106 109.
16. .., .., .. . . , , 2000, . 173 175.
17. ., . . 3, 1997, .16.
18. .. , . . . . 1995.
19. .., .. . , 1995, 100 .
20. .., .., .., .. . 5, 1989, 67, . 128 131.
21. . . . , 1993, . 257 259.
22. .. — — . 1, 1997, . 13 22.
23. Doughty L.A., Kaplan S.S., Carcillo J.A. Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit Care Med. 1996, Vol. 24, 7, p. 1137 1143.
24. Griffiths R. W., Laing J.E. A burn formula in clinical practice. Ann. R. Coll.Surg. Engl. 1981., 63, 50-53.
25. Harms B.A. et al. Microvascular fluid and protein flux in pulmonary and systemic circulation after thermal injury. Micr. Res.,1982,23,77.
26. Hennenberger A., Partecke B.D. Therapy of the severely burned child from the pediatric intensive care vewpoint. Unfalcchirurg. 1995, Apr. 98 (4): 193 — 197.
27. Herdon D.N., Barrow R.E., Linases H. Et al. Burns. 1988, vol. 14., p. 349-356.
28. Holleman J.N. et al. Palmonary effects intravevous fluid therapy in burn resuscitation. Surg. Gynecol. Obstet.,1978, 147, 161 — 166.
29. Horgan P.G., Mannick J.A., Dubravec D.B. et all. Effect of low dose recombinant interleukin 2 plus indomethacin on mortality after sepsis in a murine burn model. British journal of surgery, 77 (4) 401-4 1990.
30. Hughes J.R. et al. Seizures following burns of the skin : II.Condition associated with these seizures.-Dis. Nerw. sust., 1973, 35, 347-353.
31. Jacobs R.F., Tabor D.R. Immune cellular interactions during sepsis and septic injury. Crit. Care. Clin. 1989, 5: 9-26.
32. Jones W.G., Barber A.E., Kapur S., et all. Pathophysiologic glucocorticoid levels and survival of translocating bacteria. s of surgery, 126 (1) 50-5 1991.
33. Jones W.G., Barber A.E., Minei J.P. et all. Antibiotic prophylaxis diminishes bacterial translocation but not mortality in experimental burn wound sepsis. Journal of trauma. 30 (6) 737-40 1990.
34. Luce P.V. Acute lung injury and the acute respiratory distress syndrome. Crit. Care Med. 1998, vol. 26, 2, p. 369 376.
35. Marinov Z., Kvalteni K., Koller J. Fluid resuscitation in thermally injured pediatric patient. Acta Chir. Plast. 1997, 39(1) : 28 — 32.
36. Martin J. Evaluation of cortisone in the treatment of burns. Surgery, 1955, vol. 38, 3.
37. Mendez M.V., Molloy R.G., O`Riordain D.S., Holzheimer R.G., Nestor M.S., et all. Lymphokine activated killer cells enhance IL-2 prevention of sepsis- death in a murine model of thermal injury. Journal of surgical re, 54 (6) 565-701993.
38. Merrell S.W. et al. Fluid resuscitation in thermaly injured children. Am. J. Surg., 1986, Dec. 1, 152 (6): 664 — 669.
39. Metkus A.P., Trabulsy P.P., Schlobohm R. A furebigter with pancreatitis. American Journal of Public Health (GAPH) ISSN: 0090 — 0036, vol. 86, ISS 1, Jan 1996, p. 81-83.
40. Moggi C., Memmini G., Turini M., Ciulli L. Severe inflammatiry disease in children. Rationale for corticosteroid immunomodulating therapy : pathogenic therapy. Ped. Med. Chic. 1996. Jul,18(4) : 395-401.
41. Monafo W.W. Initial management of burns. New England. Journal of Medicine . ISS:0028-4793, vol 335, ISS:21, Nov 21,1996, p.1581-1586.
42. Montgomery A.B., Stager M.A.,Carrico C.J. Causes of mortality in patients with the ARDS. Am. Rew. Respir. Dis. 1985, 132, p.485-489.
43. Movafo W:W: et al. The treatment of burned children. Clin Plast Surg 1977, Oct 4 (4): 537 — 546.
44. Nagesha C.N., Shenoy K.J., Chandrashekar M.R. Study of burn sepsis with special reference to Pseudomonas aeruginosa. Journal of the Indian medical association> 94 (6) 230-3 1996.
45. Pinsky M.R., Matuschar G.M. Multiple systems organ failure : Failure of host defense mechanism. Crit. Care Clin. 1989; 5: 199-220.
46. Powers S.R., Mannal R., Necleroim et al. Pphysiologic consegueses of positive end expiratory pressure (PPEP).
47. Renz B.M., Sherman R. Exposure of buttock burn wounds to s in scald-abused infants and children: s-staining of eschar and burn wound sepsis. American surgeon, 59 (6) 379-83 1993.
48. Resnick S.D. Staphylococcal toxin-ted syndrome in childhood. Seminars in dermatology, 11 (1) 11-8 1992.
49. Reynolds E.M., Pyan D.P. et al. Left ventricular failure complicating severe pediatric burn injures. J.Ped. Surg. 1995, Feb., 30(2) : 264 — 269.
50. Rixen D., Siegel J.H., Friedman H.P. SepsisSIRS, physiologic classification, severity stratification, relation to cytokine elaboration and outcome prediction in posttrauma ctitical illness. Journal of trauma, 41 (4) 581-98 1996.
51. Saadia K., Lipman J. Multiple organ failure after trauma. British Medical Journal (IBMJ) IAAN : 0959-8146, vol. 313, ISS : 7057, : Sap 7, 1996, p. 573 — 574.
52. Schiller W.R. Burn management in children. Pediatr. Ann.1996, Aug 25: 431.
53. Schlag G., Redl H. tors of injury and inflammation. World journal of surgery, 20 (4) 406-10 1996.
54. Schoemaker et al. Prospectiv trial of supranormal values of surve voss as therapeutic goals in high-risk surgical patients. Shest 1992,v102,p 208
55. Taylor D.E., Piantadosi C.A. Oxidative bolism in sepsis and sepsis syndrome. Journal of critical care, 10 (3) 122035 1995.
56. Thomson P.B., Herndon D.N. et al. Effect on mortaliti of inhalation injury. J. Trauma, 26: 163 — 165, 1986.
57. Tuite P.C. Crit Care Nurs. Recognition and management of shock in the pediatric patient. 1997, May, 20 (1) : 52 — 61.